Eliem Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2021
September 13, 2021 at 04:10 pm EDT
Share
Eliem Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company loss from operations of $8,707,000 compared to $1,608,000 a year ago. Net loss and comprehensive loss was $8,719,000 compared to $1,631,000 a year ago. Net loss attributable to common stockholders was $10,860,000 or $3.11 per basic and diluted share compared to $2,083,000 or $1.12 per basic and diluted share a year ago.
For the six months, the company loss from operations of $15,586,000 compared to $3,559,000 a year ago. Net loss and comprehensive loss was $27,320,000 compared to $3,547,000 a year ago. Net loss attributable to common stockholders was $30,546,000 or $8.80 per basic and diluted share compared to $4,438,000 or $2.39 per basic and diluted share a year ago.
Eliem Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy, with Sage Therapeutics receiving approval from the United States. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS). It has designed several lead series based on novel chemistry and selected a lead clinical candidate, ETX-123. The ETX-123 molecule displays potent activation of Kv7.2/3 in vitro with an approximately 0.7 nM EC50.
ELIEM THERAPEUTICS, INC. 